Viritis Antiviral Platform
Viritis platform is an AI-driven antiviral discovery system based on programmable PNA-peptide therapeutics designed to selectively target viral RNA inside infected cells.
The platform enables rapid generation of antiviral candidates against emerging viral threats.
From Viral Sequence to Therapeutic Candidate
Viritis platform follows a structured development workflow that translates viral genomic information into therapeutic candidates.
Scientific Foundation
Viruses depend on specific RNA sequences to replicate within host cells. Traditional antiviral approaches often target viral proteins, which can mutate rapidly and reduce treatment effectiveness.
Viritis platform focuses on conserved viral RNA sequences that remain stable across variants, enabling a more robust and adaptable therapeutic approach.
By targeting essential genetic elements, the platform is designed to maintain effectiveness across evolving viral strains.
Fluorescent imaging demonstrating targeted binding of viral particles to host cells.
PNA-Peptide Molecular Architecture
Viritis platform is built on a molecular architecture combining peptide nucleic acids (PNA) with peptide-based delivery components.
PNA molecules enable strong and specific binding to viral RNA sequences, while peptide elements support efficient intracellular delivery.
This hybrid structure allows precise targeting of viral genetic material while maintaining stability and programmability.
- High binding affinity to RNA targets
- Resistance to enzymatic degradation
- Programmable sequence design
- Improved intracellular delivery
Key Advantages of the Platform
Viritis platform is designed to address several limitations of traditional antiviral drug development.
Programmable Molecular Design
Therapeutic molecules can be designed to target specific viral RNA sequences with high precision.
Broad Viral Applicability
Targeting conserved viral RNA regions allows the platform to potentially address multiple viruses and viral variants.
Scalable Pipeline
Multiple antiviral programs can be developed using the same technological backbone.
Reduced Resistance Potential
By targeting viral genetic sequences shared between most strains, our antisense reduce the likelihood of resistance compared with traditional antivirals.
Designed for Emerging Viral Threats
New viral outbreaks continue to emerge around the world, often evolving faster than traditional drug development timelines.
Viritis platform was designed to enable a faster response to these threats by allowing new antiviral candidates to be designed and developed rapidly once viral genomic information becomes available.
This capability may support the development of therapeutic programs targeting both known viruses and newly emerging pathogens.
Key Advantages of the Platform
97.1% Cellular protection
- High stability
- Safety- minimal side effects
- Virtually no toxicity
Faster Drugs Development process
- AI Algorithms for faster target identification
- AI Algorithms for safety prediction
- Customizable lead molecule
No cold chain required
- Extended Shelf Life
- Lyophilized Shipments
- Improved Storage & Transport
- Rapid Reconstitution
Faster regulatory pathway
- Pharma companies could use the (505b2) pathway to get FDA approval for each new drug in 12 months
- We Conduct only preclinical studies (no need for FDA approval)